CVS Aetna's New Generative AI Assistant Aims to Simplify Health Care
Werte in diesem Artikel
CVS Health CVS Aetna’s latest offering aligns with its strategic efforts to move away from the transactional approach to health care to a consumer health experience. The company is rolling out a generative AI-powered conversational experience in its digital channels that will simplify health care, allowing members to quickly and easily navigate their benefits for a personalized experience. Unlike other industry alternatives, where conversational AI is relegated to a chat window, Aetna is embedding generative AI across its end-to-end digital experience.The embedded approach ensures the Aetna assistant synthesizes all relevant information for the member. It will deliver immediate, easy-to-digest answers for the user, removing the need to weed through links or complex content. According to the company, members will not need to use technical healthcare terminology such as “prior authorization" or “claims" to get answers, but instead can use plain language and receive a response that is personalized, easy to understand and visually dynamic.Aetna initially launched the new capability to a beta population in October and will expand access throughout the year and in the first half of 2026. Near-term enhancements will include proactive AI insights for member and multimodal interaction support, including voice, text and screen-reader capability.The assistant will also be embedded within Aetna Care Paths, a new digital offering available through the Aetna Health app, announced as part of the company’s ongoing technology investment to improve the experience for medical professionals and their patients. Featuring a U.S. patent-pending technology, Aetna Care Paths gives clarity about procedures and benefits that may be encountered and personalized care recommendations, all in one convenient location.News From CVS Health Rivals — CAH & CNCCardinal Health CAH recently completed the acquisition of Solaris Health, a leading urology management services organization (“MSO”). The buyout adds more than 750 providers across more than 250 practice locations in 14 states and adds immediate scale to the Urology Alliance within Cardinal Health's leading multi-specialty MSO platform, The Specialty Alliance. Further, the company delivered a 22% year-over-year revenue growth in the first quarter of fiscal 2026, while non-GAAP diluted earnings per share (EPS) increased 36%.Centene Corp. CNC company, Wellcare announced plans to offer Medicare Advantage (“MA”) to over 51 million beneficiaries in 32 states and Prescription Drug Plan (“PDP”) products to more than 8 million members across all 50 states. This includes 51 new counties across eight markets, with a focus on D-SNPs, enhancements to the Wellcare Spendables card and improving member experience.CVS Stock Performance, Valuation and EstimatesYear to date, CVS Health’s shares have increased 70.5% compared with the industry’s 4.9% growth. Image Source: Zacks Investment ResearchCVS Health is trading at a forward 12-month price/sales (P/S) ratio of 0.24, lower than the industry average of 0.45.Image Source: Zacks Investment ResearchSee how the analysts are projecting CVS Health’s 2025 and 2026 earnings.Image Source: Zacks Investment ResearchCVS currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.Zacks' Research Chief Names "Stock Most Likely to Double"Our team of experts has just released the 5 stocks with the greatest probability of gaining +100% or more in the coming months. Of those 5, Director of Research Sheraz Mian highlights the one stock set to climb highest.This top pick is a little-known satellite-based communications firm. Space is projected to become a trillion dollar industry, and this company's customer base is growing fast. Analysts have forecasted a major revenue breakout in 2025. Of course, all our elite picks aren't winners but this one could far surpass earlier Zacks' Stocks Set to Double like Hims & Hers Health, which shot up +209%.Free: See Our Top Stock And 4 Runners UpWant the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Cardinal Health, Inc. (CAH): Free Stock Analysis Report CVS Health Corporation (CVS): Free Stock Analysis Report Centene Corporation (CNC): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks
Übrigens: CVS Health und andere US-Aktien sind bei finanzen.net ZERO sogar bis 23 Uhr handelbar (ohne Ordergebühren, zzgl. Spreads). Jetzt kostenlos Depot eröffnen und Neukunden-Bonus sichern!
Ausgewählte Hebelprodukte auf Ai
Mit Knock-outs können spekulative Anleger überproportional an Kursbewegungen partizipieren. Wählen Sie einfach den gewünschten Hebel und wir zeigen Ihnen passende Open-End Produkte auf Ai
Der Hebel muss zwischen 2 und 20 liegen
| Name | Hebel | KO | Emittent |
|---|
| Name | Hebel | KO | Emittent |
|---|
Quelle: Zacks
Nachrichten zu CVS Health Corp
Analysen zu CVS Health Corp
| Datum | Rating | Analyst | |
|---|---|---|---|
| 05.06.2019 | CVS Health Buy | Standpoint Research | |
| 15.04.2019 | CVS Health Perform | Oppenheimer & Co. Inc. | |
| 12.04.2019 | CVS Health Market Perform | BMO Capital Markets | |
| 18.12.2018 | CVS Health Overweight | Barclays Capital | |
| 26.10.2018 | CVS Health Peer Perform | Wolfe Research |
| Datum | Rating | Analyst | |
|---|---|---|---|
| 05.06.2019 | CVS Health Buy | Standpoint Research | |
| 12.04.2019 | CVS Health Market Perform | BMO Capital Markets | |
| 18.12.2018 | CVS Health Overweight | Barclays Capital | |
| 30.01.2018 | CVS Health Strong Buy | Needham & Company, LLC | |
| 02.01.2018 | CVS Health Buy | Needham & Company, LLC |
| Datum | Rating | Analyst | |
|---|---|---|---|
| 15.04.2019 | CVS Health Perform | Oppenheimer & Co. Inc. | |
| 26.10.2018 | CVS Health Peer Perform | Wolfe Research | |
| 28.06.2017 | CVS Health Hold | Needham & Company, LLC | |
| 02.02.2017 | CVS Health Neutral | Robert W. Baird & Co. Incorporated | |
| 22.06.2016 | CVS Health Hold | Deutsche Bank AG |
| Datum | Rating | Analyst | |
|---|---|---|---|
| 25.07.2005 | Update Longs Drug Stores Corp.: Underperform | Bear Stearns |
Um die Übersicht zu verbessern, haben Sie die Möglichkeit, die Analysen für CVS Health Corp nach folgenden Kriterien zu filtern.
Alle: Alle Empfehlungen